AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets
暂无分享,去创建一个
[1] F. Collins,et al. Aiming High--Changing the Trajectory for Cancer. , 2016, The New England journal of medicine.
[2] Stephen P. Boyd,et al. Distributed Optimization and Statistical Learning via the Alternating Direction Method of Multipliers , 2011, Found. Trends Mach. Learn..
[3] Krister Wennerberg,et al. Consistency in drug response profiling , 2016, Nature.
[4] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[5] Amos Bairoch,et al. The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.
[6] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[7] P. Sorger,et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.
[8] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[9] Shiqian Ma,et al. On the Global Linear Convergence of the ADMM with MultiBlock Variables , 2014, SIAM J. Optim..
[10] M. Gilson,et al. Public domain databases for medicinal chemistry. , 2012, Journal of medicinal chemistry.
[11] Sarah Watson,et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer , 2015, Nature Reviews Clinical Oncology.
[12] J. H. Zar,et al. Significance Testing of the Spearman Rank Correlation Coefficient , 1972 .
[13] A. Butte,et al. Leveraging big data to transform target selection and drug discovery , 2016, Clinical pharmacology and therapeutics.
[14] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[15] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[16] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[17] Gary D Bader,et al. Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance , 2016, Cell.
[18] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[19] Benjamin Haibe-Kains,et al. Revisiting inconsistency in large pharmacogenomic studies , 2015, bioRxiv.
[20] P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .
[21] Marc Hafner,et al. Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines , 2013, Science Signaling.
[22] Krister Wennerberg,et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.
[23] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[24] Joshua A. Bittker,et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.
[25] Marc R. Birtwistle,et al. Drug response consistency in CCLE and CGP , 2016, Nature.
[26] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[27] Su-In Lee,et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia , 2018, Nature Communications.
[28] Laura M. Heiser,et al. Modeling precision treatment of breast cancer , 2013, Genome Biology.
[29] Stephen P. Boyd,et al. Proximal Algorithms , 2013, Found. Trends Optim..
[30] Joshua C. Gilbert,et al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.
[31] Margarita Lopatin,et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Tsuyoshi Murata,et al. {m , 1934, ACML.